Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Watch Prof. Gietema, Dr. Trama, Dr. Valverde, and Prof. Girard discuss collaboration in rare cancer research in this video. Submit your abstract and engage with experts to advance patient outcomes
Gain insights into the future of cancer drug development: ESMO TAT represents an excellent opportunity to stay up to date with the latest early phase trials in oncology while learning multi-stakeholder perspectives
A gathering for the GI oncology community to advance care with groundbreaking science, multidisciplinary discussions, and excellent networking opportunities
Help us lead the way at this platform to collaborate, explore and discuss the latest advances in the breast cancer field
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Strategic Recommendations Highlighted to Tackle Europe’s Growing Cancer Burden
New indication concerns treatment of adult patients with locally advanced, unresectable NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations
Findings from the AQUILA study
Despite being active in this disease setting, the antibody-drug conjugate was associated to high rates of neutropenic complications
Treatment options for patients with biliary tract cancers are rapidly evolving. This update provides new recommendations for molecular diagnostics as well as for local therapies of locally advanced tumours and for systemic therapies of recurrent/metastatic disease.
ESMO welcomes the recent adoption of the non-binding Council Recommendations on smoke-free environments which include new measures covering emerging tobacco and related products such as e-cigarettes and heated tobacco products (HTPs)
Evidence for efficacy is based on the results from the HERIZON-BTC-01 study
Findings from the EMBER-3 study
Key progress follows targeted proposals and continued engagement with EU policymakers
New indication concerns treatment of adult patients with locally advanced, unresectable NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations
Findings from the AQUILA study
Evidence for efficacy is based on the results from the HERIZON-BTC-01 study
Findings from the EMBER-3 study
Clinicopathologic, genomic, immunophenotypic, transcriptional features, and treatment outcomes
Findings from the IDENTIFY study
Findings from the FELIX study
New indication concerns a combination with pemetrexed and platinum for the first-line treatment of adult patients with unresectable non-epithelioid malignant pleural mesothelioma
Evidence for efficacy is based on the results from the AUGMENT-101 study
The ESMO Immuno-Oncology Congress 2024 will take place in Geneva, Switzerland, from December 11-13, with an option to attend virtually. Leading experts will present and discuss the research advancements in the rapidly evolving field of immuno-oncology
The ESMO Asia Congress 2024 is the annual event dedicated to multidisciplinary oncology in the Asian region
The Molecular Analysis for Precision Oncology Congress 2024 (MAP) is the appointment where globally recognised experts will present and discuss research in precision medicine, technologies for cancer profiling, mechanisms driving tumour expansion, metastatic dissemination, clonal evolution, and biomarker-driven development of targeted therapeutics
Immunotherapy, which works by enabling the body’s immune system to recognise and destroy cancer cells improves long-term overall survival in patients with advanced melanoma in results from large international studies reported at ESMO 2024
Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a first-in-human study found ‘promising’ antitumour activity with a novel antibody drug conjugate (ADC) targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers
The ESMO Congress 2024 taking place 13-17 September in Barcelona, Spain, offers a comprehensive view of the current drug development landscape, with existing medicines demonstrating benefit in additional applications and new agents emerging in large numbers as the range of potential molecular targets for therapy continues to expand
The ESMO Congress 2024 will hold a press conference to introduce and discuss the “Eyes to the Future” Presidential Symposium 3, that will be presenting prominent approaches that have the potential to become increasingly effective and influential components of cancer treatment in the (near) future.
The European Society for Medical Oncology (ESMO) is calling on all actors of the oncology community to commit to improving the well-being of the cancer workforce and join in 11 actions outlined in a paper published today in ESMO Open
According to two international studies presented at the ESMO Congress 2024, women who breastfeed after receiving treatment for breast cancer, including those with a germline BRCA mutation (an inherited change in BRCA genes that significantly increases the risk of developing certain cancers, especially breast cancer), do not face an increased risk of recurrence or developing new breast cancers
ESMO welcomes the outcome of the hearings for Olivér Várhelyi, Commissioner-designate for Health and Animal Welfare, where several topics relevant for the oncology community were addressed in a positive or at least promising way
The ESMO Award for Immuno-Oncology 2024 is presented to Ton N. Schumacher in recognition of his exceptional contributions to cancer immunology and to our understanding of the mechanism of how immunotherapy works
Bringing another annual reunion of the global oncology community to a resounding close, the 34,000 attendees of the ESMO Congress 2024 had the opportunity to gather around to listen to the most important results presented in different tumour types and research areas
ESMO is pleased to announce the 2024 ESMO Fellowship awardees
The ESMO Precision Medicine Working Group (PMWG) together with a multidisciplinary team of international experts, have developed the ESMO Tumour-Agnostic Classifier and Screener (ETAC-S)
The recipients of the 2024 ESMO Society Awards have been announced today by ESMO
Hundreds of trials are being delayed in Europe due to unintended consequences of the IVDR posing an existential threat to Europe’s role as a leader in global oncological research
The Impact Factor (IF) of ESMO journals has remained strong this year, according to the 2024 Journal Citation Reports published by Clarivate Analytics
ESMO has announced today the results of its Presidential elections following the closure of the voting system on Monday, 10 June 2024.
Despite being active in this disease setting, the antibody-drug conjugate was associated to high rates of neutropenic complications
Different combinations of immunotherapy agent and radiotherapy or chemoradiotherapy were tested in some patient populations in two studies
Next steps for research include personalising regimens and learning how to predict response and toxicity
Studies explore the prognostic and predictive values of circulating DNA tumour fraction and single-cell RNA sequencing of peripheral blood mononuclear cells
Results underline the need to further characterise dysbiosis, and to develop diagnostic and actionable tools for mainstream integration
A lack of benefit coupled with increased toxicity was reported in patients with stage I/II inoperable disease in the KEYNOTE-867 trial
According to the 2024 ESMO Immuno-Oncology Awardee, Ton Schumacher, tackling the T-cell receptor challenge with vast datasets and cutting-edge high-throughput methods may pave the way for advances in the field
However, some challenges still limit its implementation in clinical practice
Study confirms favourable safety profiles and encouraging efficacy of an anti-claudin 18.2 antibody-drug conjugate
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
South Africa
South Africa
Switzerland
France
United Kingdom
Switzerland
France
Switzerland
Peru
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Examination 2025 will be held on Saturday 18 October during the ESMO Congress 2025.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
